Proactive

Proactive FYI: Our posts aren’t investment advice. We share info we trust, but it’s not guaranteed. Check facts before investing. Some posts may earn us fees.
(233)

Digital asset ETPs hold above $200B for second month in August, Fineqia analysis shows: Global digital asset exchange-tr...
05/09/2025

Digital asset ETPs hold above $200B for second month in August, Fineqia analysis shows: Global digital asset exchange-traded products (ETPs) ended August 2025 with $205.23 billion in assets under management (AUM), marking the second consecutive month above the $200 billion threshold, an analysis from Fineqia International Inc (CSE:FNQ, OTC:FNQQF) has shown.

In its report, Fineqia said that this total represented a 1.3% decline from July’s record high of $207.82 billion.

The broader digital asset market capitalization rose 2.2% in August, climbing from $3.75 trillion to $3.84 trillion.

This marked one of the few instances where overall market growth outpaced ETP AUM, reflecting shifts in investor flows between Bitcoin, Ethereum, and altcoins, Fineqia noted.

Bitcoin-backed ETPs closed the month at $159.5 billion, down 6.5% from July’s $170.66 billion, mirroring a 6.4% decline in the price of Bitcoin to $108,228.

Fineqia’s report noted that outflows were minimal, with Bitcoin ETP investors showing longer-term holding patterns despite short-term...

Global digital asset exchange-traded products (ETPs) ended August 2025 with $205.23 billion in assets under management (AUM), marking the second consecutive...

Small cap weekly spotlight: pharma stocks see key progress: More than one small-cap pharma share saw a breakthrough in t...
05/09/2025

Small cap weekly spotlight: pharma stocks see key progress: More than one small-cap pharma share saw a breakthrough in the past week, with some key approvals and news of commercial tie-ups lifting valuations.

ImmuPharma PLC (AIM:IMM) was a standout, rising close to 80% this week to 4.93p, after it filed a new patent for an autoimmune drug candidate. It will cover both diagnostics and precision therapy.

Another was Arecor Therapeutics PLC (AIM:AREC) was boosted on Thursday, and the share is up 13% to 71.3p, as it received FDA support for a Phase 2 trial of a concentrated insulin product, with the trial expected in 2026.

On the same day, Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) secured FDA priority review for expanding Accrufer to adolescent iron deficiency patients. It sees the product advancing towards the market. At 8.57p, Shield was up 20% for the week.

Aptamer Group PLC (AIM:APTA), on Tuesday, announced a therapeutic development agreement with Invizius to deploy Optimers targeting the complement system in support of...

More than one small-cap pharma share saw a breakthrough in the past week, with some key approvals and news of commercial tie-ups lifting valuations....

Team Internet: sharper, more balanced and lower debt - ICYMI: Team Internet Group PLC earlier this week outlined progres...
05/09/2025

Team Internet: sharper, more balanced and lower debt - ICYMI: Team Internet Group PLC earlier this week outlined progress on its strategic transformation, debt reduction, and product focus during the first half of 2025.

Chief executive Michael Riedl told Proactive that the company had modernised its product portfolio, expanded into new geographies, and streamlined its cost base. These changes, he said, contributed to a more balanced and resilient business.

CFO Billy Green focused on the financial performance, noting that net debt stood at £109.9 million as of 30 June 2024 but had since fallen below £100 million. The company said it continues to reduce net debt while maintaining investment in its platforms.

Proactive: I'm joined by Team Internet CEO Michael Riedl as well as CFO Billy Green. Good to speak with you both.

Michael, I'm going to start with you. The first half of 2025 was clearly a period of big change. Could you walk investors through the main drivers behind your transformation strategy and how it’s positioning the...

Team Internet Group PLC earlier this week outlined progress on its strategic transformation, debt reduction, and product focus during the first half of...

GoviEx Uranium secures backing from 40% of securityholders for reverse takeover of Tombador Iron: GoviEx Uranium Inc (TS...
05/09/2025

GoviEx Uranium secures backing from 40% of securityholders for reverse takeover of Tombador Iron: GoviEx Uranium Inc (TSX-V:GXU, OTCQB:GVXXF) announced that securityholders representing more than 40% of its outstanding securities have entered into binding voting support agreements in favor of its planned reverse takeover of Tombador Iron.

The transaction would create Atomic Eagle, an ASX-listed uranium developer that GoviEx said will have a strengthened balance sheet and a mandate to advance the Muntanga project in Zambia.

On completion, GoviEx shareholders will hold 75% of Atomic Eagle, while Tombador shareholders will retain 25%.

Tombador has filed its meeting circular with the Australian Securities Exchange to seek shareholder approval, with a vote scheduled for October 8, 2025.

In parallel, GoviEx securityholders are set to vote on the deal at a meeting on October 24, following amendments to the arrangement agreement to align treatment across shareholder classes.

As part of the transaction, Tombador will also undertake a concurrent financing of at least A$5...

GoviEx Uranium Inc (TSX-V:GXU, OTCQB:GVXXF) announced that securityholders representing more than 40% of its outstanding securities have entered into...

Alvopetro Energy sees 'extremely strong' August 2025 sales volumes: Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF) reported...
05/09/2025

Alvopetro Energy sees 'extremely strong' August 2025 sales volumes: Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF) reported August sales volumes of 2,375 barrels of oil equivalent per day (boepd), based on field estimates.

The natural gas producer said August sales volumes in Brazil averaged 2,257 boepd, including natural gas sales of 12.7 million cubic feet per day (MMcfpd), associated natural gas liquids sales from condensate of 132 bopd and oil sales of 9 bopd.

The company noted that the large relative contribution of production from its 100% Murucututu field in Brazil in August relates to the start of production from the 183-D4 well, which kicked off production later in the month.

From August 20 through September 3, the 183-D4 well produced at an average rate of 162,000 cubic metres per day (e3m3/d) (5.7 MMcfpd, 954 boepd) and the company said it recovered 5,482 barrels of completions fluid and 1,033 barrels of natural gas liquids from condensate.

Alvopetro added that there are 10,322 barrels of 15,806 barrels of completions...

Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF) reported August sales volumes of 2,375 barrels of oil equivalent per day (boepd), based on field estimates.  The...

Active Energy Group shares jump 30% on solar and battery pipeline news: Shares in Active Energy Group PLC (AIM:AEG, OTCQ...
05/09/2025

Active Energy Group shares jump 30% on solar and battery pipeline news: Shares in Active Energy Group PLC (AIM:AEG, OTCQB:ATGVF) surged as much as 30% in early trading on Tuesday after the company unveiled plans for its first pipeline of solar and battery storage projects.

The initial rollout targets 10 commercial warehouse rooftops with a combined capacity of 2.3 megawatts (MW).

AEG said it is in the final stages of securing long-term leases and power purchase agreements, which are expected to generate more than £10 million in contracted revenue over 20 years.

The announcement marks a key step in the company’s pivot to renewable energy, with chief executive Paul Elliott describing it as “a significant milestone” in AEG’s transformation.

The company is working with renewables adviser Brian Glendinning to scale the portfolio further, targeting both rooftop and ground-mounted installations.

AEG plans to own and operate the assets, providing stable, inflation-linked income streams with scope for future refinancing to support...

Shares in Active Energy Group PLC (AIM:AEG, OTCQB:ATGVF) surged as much as 30% in early trading on Tuesday after the company unveiled plans for its first...

CORD beats its NAV target and delivers standout share price gains - Kepler: Cordiant Digital Infrastructure Ltd (LSE:COR...
05/09/2025

CORD beats its NAV target and delivers standout share price gains - Kepler: Cordiant Digital Infrastructure Ltd (LSE:CORD) has quietly delivered a strong run of form, outperforming its own targets and clocking up share price returns that would make even seasoned investors take notice.

According to a new note from Kepler Partners, the fund has beaten its target net asset value (NAV) return of 9% a year, with actual annualised performance since launch sitting slightly higher at 9.2%. That may not sound like much on paper, but it’s a solid result when paired with this year’s 40% jump in the share price—especially given the wider infrastructure sector’s more muted performance.

CORD focuses on digital infrastructure—the behind-the-scenes assets that keep the internet running—like fibre networks, data centres and mobile towers. It’s a specialist in a world full of generalists, and that focus has allowed it to grow assets through a hands-on “Buy, Build & Grow” strategy. The team takes majority stakes in companies, then boosts their value through...

Cordiant Digital Infrastructure Ltd (LSE:CORD) has quietly delivered a strong run of form, outperforming its own targets and clocking up share price returns...

Inside Biotech: Why heart health is biotech’s quiet giant: Cardiovascular disease remains the world’s biggest killer, re...
05/09/2025

Inside Biotech: Why heart health is biotech’s quiet giant: Cardiovascular disease remains the world’s biggest killer, responsible for nearly 18 million deaths each year, according to the World Health Organisation. For investors, it is also one of the most enduring areas of healthcare spending — spanning pharmaceuticals, diagnostics and medical devices that together make up a multibillion-dollar market.

Yet despite the sheer size of the opportunity, cardiovascular innovation often receives less attention than hot-button areas like oncology or neuroscience. But with populations ageing rapidly, pressure on hospital systems mounting, and device technology entering a new phase, heart health is moving back to the centre of biotech’s investment conversation.

The growing burden of structural heart disease

Among the most pressing challenges is structural heart disease, particularly aortic stenosis — the narrowing of the aortic valve that restricts blood flow and can lead to heart failure. It is one of the most common and serious valve...

Cardiovascular disease remains the world’s biggest killer, responsible for nearly 18 million deaths each year, according to the World Health Organisation....

Krakatoa targets antimony-gold at Zopkhito: Krakatoa Resources Ltd earlier this week began its first-ever drilling campa...
05/09/2025

Krakatoa targets antimony-gold at Zopkhito: Krakatoa Resources Ltd earlier this week began its first-ever drilling campaign at the Zopkhito Sb-Au Project in Georgia. Chief executive officer Mark Major described the program as a “significant event for the project” and a major step in Krakatoa’s efforts to modernise the resource estimate.

Highlights

Krakatoa Resources has started its maiden drill campaign at the Zopkhito Sb-Au Project in Georgia.
The program will include 7,000–10,000 metres of diamond drilling.
Targets areas were previously mapped through underground development.
A foreign resource estimate had outlined 225,000 tonnes at 11.6% Sb and 7.10 million tonnes at 3.7 g/t Au.
The aim is to validate and potentially convert the estimate to JORC 2012-compliant status.
One rig is active, with another due to mobilise soon.
The drilling will inform development options and test scale and grade potential.
Georgia’s strategic trade access and favourable business environment support the...

Krakatoa Resources Ltd earlier this week began its first-ever drilling campaign at the Zopkhito Sb-Au Project in Georgia. Chief executive officer Mark Major...

RC drilling underway at Yandal Resources' Caladan gold target: Yandal Resources Ltd earlier this week began a reverse ci...
05/09/2025

RC drilling underway at Yandal Resources' Caladan gold target: Yandal Resources Ltd earlier this week began a reverse circulation (RC) drilling program at the Arrakis prospect, part of its Caladan target area within the Ironstone Well-Barwidgee Gold Project in Western Australia. Yandal Resources Ltd exploration manager Chris Oorschot talked with Proactive about the start of the drilling campaign

Highlights

Yandal Resources commenced a ~2,000-metre RC drilling program at the Arrakis prospect.
Drilling will test mineralisation continuity and host structure geometry beneath broad-spaced air-core intercepts.
Arrakis lies within the broader Caladan target in the Ironstone Well-Barwidgee Gold Project.
Recent air-core drilling defined over 2.2 kilometres of mineralisation.
Drilling is expected to complete in 10–16 days, with assay results in 5–7 weeks.
Results from 14 air-core holes at Caladan are still pending.
Heritage surveys are planned to enable tighter-spaced drilling.
Additional exploration at New England Granite is...

Yandal Resources Ltd earlier this week began a reverse circulation (RC) drilling program at the Arrakis prospect, part of its Caladan target area within the...

Lumos steps up PheCheck, FebriDx fets BARDA backing: Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF)'s Sam Lanyon ea...
05/09/2025

Lumos steps up PheCheck, FebriDx fets BARDA backing: Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF)'s Sam Lanyon earlier this week discussed with Proactive two material developments in its diagnostics pipeline. The company has signed a US$1.5 million contract with Aptatek Biosciences Inc. to progress development of the PheCheck™ PKU monitoring device, and separately secured new BARDA funding to support a paediatric trial of its FebriDx® rapid test.

Lumos signed a US$1.5 million development contract with Aptatek for the PheCheck™ PKU device.
The contract runs for 10 months from September 2025.
Lumos will mature test design, blood processing, and conduct verification testing.
The device aims to support in-home PKU monitoring and has FDA Breakthrough Device designation.
FebriDx® will be studied in children aged 2–12 with nearly US$6.2 million in BARDA funding.
The paediatric trial begins in Q3 2025 and aims to support a dual FDA 510(k) and CLIA waiver submission.
If approved, FebriDx’s addressable US market could...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF)'s Sam Lanyon earlier this week discussed with Proactive two material developments in its diagnostics...

Lightning Minerals to drill Mt Turner in September: Lightning Minerals Ltd (ASX:L1M) earlier this week confirmed it woul...
05/09/2025

Lightning Minerals to drill Mt Turner in September: Lightning Minerals Ltd (ASX:L1M) earlier this week confirmed it would begin its first drilling campaign at the Mt Turner Gold Project in Queensland, targeting five key zones of gold mineralisation beneath historic open pits. Alex Biggs, managing director of Lightning Minerals, told Proactive: “We’re looking forward to starting our first drill campaign at Mt Turner. There are multiple targets which the team has a high degree of confidence in.”

Highlights

Lightning Minerals to begin maiden drilling at Mt Turner Gold Project in mid-September 2025.
Up to 1,300 metres of diamond drilling planned across five historic pits.
Targets include Rocky Reward, Drummer Girl, Drummer Boy, Drummer West and Drummer East.
Project secured via recent acquisition of Lotus Minerals.
GeoDrill Australia appointed as drilling contractor.
Historical results include 12m @ 6.5g/t gold and 3m @ 5.1g/t gold with 51g/t silver.
Limited prior drilling below 100 metres leaves scope for deeper...

Lightning Minerals Ltd (ASX:L1M) earlier this week confirmed it would begin its first drilling campaign at the Mt Turner Gold Project in Queensland,...

Address

London

Telephone

+442079890813

Website

Alerts

Be the first to know and let us send you an email when Proactive posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category

New Look, More Proactive

Here's a look at Proactive's new website.....

Almost a year ago we asked you, our audience, how we could improve. In a few weeks you’ll see the result of that comprehensive, helpful and honest feedback – our new site.

It’s cleaner, easier to navigate, but remains true to our ethos by bringing you unparalleled coverage of the next-generation Googles, Amazons and Apples.

The first thing you’ll notice is a change of corporate colours and logo. We’ve also become Proactive, which our branding guru says is both bold and simple.